Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Thoracic 2CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Variants × Sarcoma × 1 year × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡